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Abstract 
Exonic duplications account for 10-15% of all mutations in Duchenne muscular dystrophy (DMD), a 
severe hereditary neuromuscular disorder. We report a CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeat)/Cas9-based strategy to correct the most frequent (exon 2) duplication in the DMD 
gene by targeted deletion, and tested the efficacy of such an approach in patient-derived myogenic 
cells. We demonstrate restoration of wild-type dystrophin expression at transcriptional and protein 
level in myotubes derived from genome-edited myoblasts in the absence of selection. Removal of the 
duplicated exon was achieved by the use of only one gRNA directed against an intronic duplicated 
region, thereby increasing editing efficiency and reducing the risk of off-target effects. This study 
opens a novel therapeutic perspective for patients carrying disease-causing duplications. 
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Introduction 
Duchenne muscular dystrophy (DMD; OMIM #310200) is an X-linked recessive muscle-wasting 
disease, characterized by progressive weakening of skeletal, respiratory and cardiac muscle followed 
by necrosis and fibrosis. DMD affects ~1:4087 live male births and is associated with delayed motor 
milestones.1 DMD is caused by absent or reduced levels of the dystrophin protein, which plays an 
important role in the stabilization of sarcolemma. In the absence of dystrophin, muscle strength steadily 
declines in the first decade of life, accompanied by progressive degeneration and regeneration of 
muscle fibers and their replacement by fat and connective tissue.2 Lack of dystrophin affects as well the 
cardiac muscle and the diaphragm, resulting in respiratory and heart failure and premature death.  
 DMD occurs as a result of mutations in the DMD gene that lead to premature termination of 
translation. The most frequent mutations are exonic deletions and duplications that induce a frame-shift 
in the protein-coding sequence.3 Skipping of in-frame mutated exons and deletions by antisense 
oligonucleotides (AONs) has long been considered a promising therapeutic strategy for DMD. This 
strategy aims at artificially inducing favourable exclusion of mutated/out-of-frame exons to restore the 
correct reading frame.4 The exciting prospect of an effective AON-based exon skipping therapy was 
raised by promising data from early clinical trials that were however not confirmed by double-blind, 
placebo-controlled phase IIb and III trials, which failed to meet efficacy endpoints.5 Independently 
from its efficacy, AON-based exon skipping can target only a limited number of mutations: skipping of 
exon 51, which could restore a correct reading frame in the largest proportion of DMD mutations, 
would be applicable to just ~10% of DMD patients.6-7 Moreover, this and similar treatments are not 
applicable to out-of-frame mutations and are of limited efficacy for exon duplications8-9 therefore 
requiring a multi-exon skipping approach.10 
 4
 Among the reported DMD mutations, duplications represent a distinct group accounting for 
~10-15% of those reported in the Leiden database,2 although their incidence may be higher,11 
Duplications have been generally neglected by therapeutic approaches. Wein et al.12 recently reported a 
successful attempt at inducing out-of-frame skipping of exon 2, causing an alternative translation 
initiation in exon 6 and leading to expression of a functional N-truncated dystrophin. These results 
support a potential therapeutic approach for patients with mutations within the 5' exons of DMD but it 
would be ineffective for all the other duplications. 
There is no definitive cure for DMD and for long time the only treatment option has been corticosteroid 
administration, a palliative management associated with many side effects. However, two drugs have 
recently obtained conditional approval in Europe (Ataluren, a read-through drug for premature stop 
mutations)13 and USA (Eteplirsen, an antisense molecule to restore the open reading frame in patients 
with mutations correctable by skipping exon 51).14   
 Genome editing technology uses synthetic nucleases to introduce targeted modification at 
specific loci in the genome by exploiting the endogenous cellular DNA repair mechanisms. These 
engineered enzymes are commonly based on zinc finger nucleases (ZFNs),15 transcription activator-like 
effector nucleases (TALENs),16 meganucleases17 and, lately, the RNA-guided CRISPR/Cas9 system.18 
These tools have been used to create new animal models19-21 and, recently, in vitro and in vivo 
therapeutic strategies for DMD22-25 aimed at restoring disrupted reading frames by deleting instead of 
skipping mutated/out-of-frame exons. Compared to AON-mediated exon skipping, which involves 
repeated injection of the therapeutic molecules with toxicity and variable tissue uptake,26-27 the exon 
deletion strategy would require only one administration of the gene editing system to achieve full 
exclusion of the targeted exon. Restoration of the reading frame for some duplication by excising one 
copy of the duplicated exon could permit expression of a normal dystrophin transcript, as recently 
demonstrated for a multi-exonic duplication of 139 kb,28 and allow synthesis of a normal dystrophin 
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isoform as compared to the restoration of the reading frame around the more common deletions that 
can generate a less severe, Becker Muscular Dystrophy (BMD)-like phenotype. 
 We report a CRISPR/Cas9 strategy to remove the most frequent duplication in the DMD gene, 
applicable to all patients with exon 2 duplications. The deletion restores synthesis of wild-type 
dystrophin at the transcriptional and protein level, adding relevant information on the efficiency of the 
gene editing approach and the correct localization of the resulting protein. 
 
RESULTS  
Strategy for the correction of duplications in DMD and guide RNAs rational design  
Our strategy to target duplications relies on the hypothesis that a single guide RNA (gRNA) designed 
over a tandem duplicated region will cut twice, leading to the deletion of the region between the two 
double strand breaks (DSB), thereby removing the duplication. This approach has been independently 
validated by the Cohn lab (University of Toronto) to remove a duplication of the exons 18-30 in the 
DMD gene.28 
To identify editing targets able to correct the DMD duplication of the exon 2 (dup2) in all patients 
bearing this type of mutation, we collected DNA from eight patients and characterized the extension of 
the copy number variation with the DMD-CGH array.29 Data from ten more patients were collected 
from the literature29-32 and aligned with the other duplications analyzed in order to identify a region 
shared among all the patients studied (Fig. 1a). Interestingly, we identified duplicated regions spanning 
25 to 286 kb with no common breakpoints. 
A duplicated minimum common region (MCR) of about ten kilobases was uploaded in ZiFiT and 
gRNAs of 18 nucleotides were selected based on the available guidelines and on the smallest number 
of potential off-targets with a maximum of two mismatches. We also designed two gRNAs (one of 
which of 19 nt) targeting the coding sequence of the exon 2 in order to confirm the evidence that 
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shifting the reading frame in the early codons should trigger the translational restart at exon 6 as 
previously demonstrated by an exon skipping approach (Fig. 1b).12  
Guide RNAs were named according to the following code: cr (crispr), DMD, int (intron) or ex (exon) 
2, and numbered from 1 to 6 (the crDMD notation have been omitted in Figs. 2e-f and Fig. 3 to limit 
redundancy). Repeated regions and functional splicing sequences were excluded from the design. All 
gRNA sequences were cloned in the MLM3636 plasmid backbone (Table S1). 
 
Testing of gRNAs activity by plasmid transfection in HEK293T and myogenic cell lines 
To validate the ability of gRNAs to induce DSBs we transfected each gRNA and the Staphylococcus 
pyogenes’s Cas9 (spCas9, JDS246) in HEK293T cells and performed the T7E1 assay. Interestingly, the 
PCR system amplifying across the gRNA crDMDint2.1 and crDMDint2.2 regions incorporates a 
simple tandem repeat (TG) that creates a heteroduplex which is cleaved into two fragments when 
digested with the T7E1 enzyme (Suppl. Fig. 1). 
To test the gRNAs in myogenic cells we obtained primary myoblasts from two DMD patients with 
large duplications of 137 and 263 Kb, respectively encompassing the exon 2 (Fig. 1a; #994 and #515). 
These cells have been immortalized as previously described.33 Due to low transfection efficiency 
(<20%, data not shown) of myoblasts, we chose to test the presence of deletions caused by two gRNAs, 
as they can be easily discriminated from the wild type sequences. Hence, we co-transfected Cas9 and 
different combinations of two gRNA in a wild type myogenic cell line and tested the ability of the two 
gRNAs to delete a genomic region. We first tested the two gRNA crDMDint2.1 and crDMDint2.6 and 
detected a deletion of 5.6 kb resulting in about a 20% of reduction in the amplification of the wildtype 
region in treated cells when compared to untreated cells (Fig. 2a). The PCR product corresponding to 
the deleted sequence was only detectable in treated cells. Sequencing of the latter revealed the 
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coexistence of two products differing from each other for the insertion of one thymine at the breakpoint 
(Fig. 2b). 
As previously reported by Kraft et al., the use of two synthetic gRNAs targeting two different positions 
of the same chromosome induces deletions, inversions and duplications through non-homologous end 
joining (NHEJ).34 Hence, we tested the occurrence of deletions and inversions by specifically designed 
PCR (Figs. 2c-d) amplifying and sequencing the expected deletions and inversions of different range 
between the target sites of the tested gRNAs (Figs. 2e-f). A representation of deletions and inversions 
obtained with two gRNAs and the sequence of the respective breakpoints is available in the Figure S2. 
Overall, five out of seven of our gRNAs resulted to have activity in HEK293T cells (Figure S1) and 
were able to introduce deletions (80%) and inversions (72%) when used in couples in a myogenic cell 
line (Fig. 2). 
 
Targeted removal of a large duplication in myogenic cells by lentiviral delivery of CRISPR/Cas9 
without selection 
In order to increase the efficacy and maximize our results in cell lines, we cloned the more efficient 
gRNAs in the LentiCRISPRv2 vector (Addgene Plasmid #52961).35 We did not select the infected cells 
by antibiotics resistance as the immortalization process takes advantage of two lentiviruses and one 
shares the puromycin resistance also present in the LentiCRISPRv2 vector. We analysed vector copy 
number 72 hours after transduction at a multiplicity of infection (MOI) of 20 (Table 1). #515 and #994 
cells received an average of 0.6 and 2.7 copies of LentiCRISPR, respectively. 
To quantify the deletions of the duplicated region and indirectly the WT alleles created by the editing, 
we analyzed the genomic region targeted by our approach versus a region in intron 67 of the DMD 
gene by real-time PCR. We detected the highest rate of deletions in 994 cells treated with LV_int2.1 
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(about the 13%) whereas no deletions at all were revealed in 515 cells transduced with LV_Ex2.1 (Fig. 
3a).   
We then investigated the presence of inversion events by amplifying the region targeted by the gRNAs 
with only one primer close to the target region (Figure S3). We obtained no evidence of inversion event 
despite 45 cycles of PCR amplification (data not shown).  
In order to better investigate dystrophin expression, we induced myoblast differentiation to myotubes. 
RNA analysis revealed an increased ratio between wild type/duplicated transcripts ranging from 1.5 to 
about 4 fold in cells transduced by LentiCRISPR (Fig. 3b). Western blot analysis showed restoration of 
wild-type dystrophin in #994 cells transduced with LV_int2.1 (11%) and LV_int2.6 (7%) when 
compared to WT (Fig. 3c) whereas #515 cells did not show any labelling, this is probably due to the 
low rate of transduction in #515 cells with vector copy number (VCN) spanning from 0,4 to 0,8 while 
being around 3 in #994 cells. 
Immunocytochemistry showed intense expression and correct localization of dystrophin in clustered 
myotubes in differentiated #994 cells infected with LV_int2.1 and LV_int2.6, even though these 
represented only a 5% of total cell population (Fig. 3d). 
We then investigated the on-target vs. off-target activity of gRNA crDMDint2.1, which showed the 
highest activity in restoring dystrophin expression. We scored ~73% on-target activity in 110 clones 
sequenced (Figure S4, upper table) and no off-target effect by T7E1 assay (Figure S4, bottom table).  
 
DISCUSSION 
The recent development of the CRISPR/Cas9 system have brought great excitement in the research 
community and new perspectives for the treatment of several genetic diseases, and recently for DMD 
with convincing data in vitro and in vivo.36-40 For these purposes, the CRISPR/Cas9 system has been 
mainly exploited to remove out-of-frame or in-frame mutated exons and restore the dystrophin reading-
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frame by targeting the sequence to be removed with two gRNAs. This approach is applicable to out-of-
frame deletions and point mutations optimistically accounting for the 85% of all mutations, restoring 
the expression of a smaller functional protein and converting the severe phenotype into a milder, 
Becker-like one, as aimed by exon skipping approaches.41  
 Duplications represent the third cause of DMD among all the dystrophin mutations. The attempt 
to treat duplications has been recently reported, in a multi-exonic duplication in the DMD gene.28 Here, 
we described a strategy to correct the most frequent duplication in the DMD gene that could be 
extended to all other, less frequent duplications, leading to the synthesis of full-length, WT dystrophin. 
CGH analysis allowed us to identify a minimal region which is duplicated and shared among all the 
patients studied, against which we screened gRNAs with the aim of finding a deletion strategy 
potentially addressing all those patients (Fig. 1). We used lentiviral vectors to bring our gRNAs and the 
spCas9 in patient-derived myoblasts, in order to maximize the efficiency of delivery and have both 
elements in a single vector. We were able to quantify the efficiency of the Cas9-induced deletions 
directly in treated cells without selection, and assay the results at both transcriptional and protein 
expression levels by cytochemical analysis of myotubes differentiated in vitro from treated myoblasts. 
The sequence analysis of inversions and deletions breakpoints indicated that rearrangements caused by 
two gRNAs are mostly neat and show the mutational spectrum introduced by NHEJ only in few cases 
(Figure S2). Interestingly, we did not detect inversions when dup2 patient’s myoblasts were treated, 
backing up the concept that deletions occur more frequently than inversions in our system, as described 
elsewhere.34  
Treatment of immortalized myoblasts derived from two dup2 patients resulted in the deletion of the 
duplication at the genomic level (Fig. 3a) and in an increased expression of wild-type dystrophin 
transcripts (Fig. 3b). This expression was followed by a detectable and correctly localized dystrophin 
only in the #994 cell line (Fig. 3c-d), which carries a smaller duplication of 137 kb, and not in the #515 
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cell line, which carries a larger, 263kb-duplication, probably due to the limited transduction efficiency 
in this cell line. Our results are concordant with those reported by Wojtal et al. in terms of restoration 
of protein expression in cells bearing deletions of comparable size (139 and 137 kb).28 We extended the 
significance of those findings by reporting the correct localization of dystrophin at the sarcolemma in 
myotubes derived from #994 cells transduced with two out of three lentiviral vectors, despite the small 
number of myoblasts positive for DMD expression (Fig. 3d).  
Even if we did not detect off-target activity for the best guide RNA in our hands (Figure S4, bottom 
table), the recent improvements in the CRISPR design,42 specificity of the spCas943 and repertoire of 
Cas9 enzymes44-45 let foresee a safer application of the technology, which opens perspectives for the 
clinical investigation. 
In fact, by delivering Cas9 and gRNAs with AAV vectors it will be possible to specifically drive the 
correction of duplications to the muscles in vivo.37 It has been demonstrated that the AAV viral 
genomes are lost in the regenerating dystrophic skeletal muscle.46 This could mimic a transient 
expression of the CRISPR/Cas9 system, which reduces the risk of immune response and off-target 
activity while still producing stable genome modifications in satellite cells that could be able to repair 
or restore the muscles.37 
 Taken together, these data indicate that the removal of a duplication event by Cas9-mediated 
genome editing is feasible with only one gRNA directed against a duplicated intronic region (which is 
duplicated in a relevant number of DMD patients), increasing editing efficiency and reducing the risk 
of off-target effects. These findings provide proof-of-concept for a gene editing approach in DMD 
patients carrying duplications and lay out the foundation for further research into the application such 
an approach in other inherited disorders caused by gene duplications. 
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MATERIALS AND METHODS 
Patients 
We have studied eight DMD patients known to have duplications of the exon 2 by MLPA analysis. 
DNA from these patients was obtained thanks to the collaboration with Dr. France Leturcq through the 
AFM-Telethon Biobank. 
Myoblasts from two of these patients (ID #515 and #994), available through the Biobank, were 
immortalized thanks to the collaboration with the Institut de Myologie as previously described.33 
Informed consent was obtained from all patients to conduct the study, which was in accordance with 
the Helsinki Declaration. All the experimental procedures were approved by Genethon. 
 
CGH analysis 
According to manufacturer’s instructions DNA samples were processed and hybridized to the DMD-
CGH array as previously reported.29 The array was analysed with the Agilent scanner and the Feature 
Extraction software (v12.0). A graphical overview and analysis of the data were obtained using the 
Agilent Genomic Workbench (v7.0). For identifying duplications and deletions we used the standard 
set-up of the ADM-2 statistical analysis provided by Genomic Workbench software (Agilent). 
The array platform and data-related information have been submitted to the online data repository Gene 
Expression Omnibus (GEO, NCBI), with accession number GSE83658. 
A graphical representation of the duplications was produced by creating a custom track and displaying 
it in UCSC Genome Browser GRCh37/hg19 assembly (http://genome.ucsc.edu). Ten more 
characterized duplications of the exon 2 from DMD patients were collected from the literature27-30 and 
represented with a custom track (Fig. 1a). 
 
gRNA design and off-target prediction 
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The minimal common duplicated region shared among all the patients was uploaded in ZiFiT 
(http://zifit.partners.org/ZiFiT/) and used as a template to design six truncated gRNAs47 of 18 base 
pairs and one (crDMDex2) of 19 bp (Fig. 1b). Oligos used to clone the gRNAs are shown in the Table 
S1. According to the available guidelines48 on CRISPR design we selected and cloned into the 
MLM3636 backbone (Addgene number 43860) those with less than ten off-target regions with two 
mismatches as predicted by ZiFiT (Figure S4).  
 
Cell cultures  
To preliminarily screen the activity of the candidate gRNAs, we transfected HEK293T cells with the 
Cas9 plasmid JDS246 (Addgene number 43861) and with each gRNA, using Lipofectamine2000 
(Thermo Fisher Scientific). DNA extraction (Blood & Cell Culture DNA Mini Kit, Qiagen) was 
performed 72 hours after transfection for PCR amplification and T7E1 assay.  
Immortalized DMD myoblasts were maintained in Skeletal Muscle Growth Medium (Promocell) and 
differentiated into myotubes for at least seven days in Skeletal Muscle Differentiation Medium 
(Promocell) at 37°C with 5% CO2 incubation. Transfection of spCas9 and DMD gRNAs was 
performed with JetPEI (Polyplus) following manufacturer instructions. After 72 hours DNA was 
extracted to perform PCR amplification. 
 
T7EI assay 
PCR amplicons for targeted and off-target genomic regions were obtained by amplification with 
Platinum Taq DNA Polymerase High Fidelity (Thermo Scientific). The PCRs were carried out under 
the following conditions: preheating 95°C for 5 min, followed by 35 cycles of 95°C for 30s, 64°C for 
30s and 68°C for 1min 20s.  
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The PCR products were resolved on 1.5% agarose gel and then purified with Qiaquick PCR 
Purification Kit (Qiagen). For T7E1 cleavage assay purified PCR products were denatured and 
annealed in NEBuffer 2 (NEB) using a thermocycler. Hybridized PCR products were digested with T7 
endonuclease 1 (NEB, M0302L) for 15 minutes at 37°C and subjected to 2% agarose gel 
electrophoresis. Percentage of DNA modification was calculated using the formula %DNA 
modification= 100*(1-(1-fraction cleaved)1/2) reported on the NEB website 
(https://www.neb.com/protocols/2014/08/11/determining-genome-targeting-efficiency-using-t7-
endonuclease-i). All PCR primer sequences are listed in Table S2. 
 
Detection of deletions and inversions  
The gDNA samples obtained from cells transfected with two gRNAs were amplified with Platinum 
Taq DNA Polymerase High Fidelity (Thermo Scientific). We prepared two specific PCR reactions with 
a common forward primer upstream the first gRNA binding site and a second forward primer localized 
between the two gRNA binding sites to detect inversions or a reverse primer downstream the second 
gRNA binding site to detect inversions (Figs. 2c and 2d). The PCRs were conducted in order to detect 
genomic deletions and inversions under these conditions: preheating 95°C for 5 min, followed by 35 
cycles of 95°C for 30s, 60°C for 30s and 68°C for 40s. Inversions were amplified with 40 cycles.  
Inversions in cells with duplication of the exon 2 were amplified with only one forward primer 
upstream of the binding site of the gRNA used.  If inversions occur, the primer would bind to the wild 
type sequence in forward orientation and the inverted one in reverse orientation (Figure S3). PCR 
conditions were: preheating 95°C for 5 min, followed by 45 cycles of 95°C for 30s, 60°C for 30s and 
68°C for 40s. 
Amplicons were resolved through 1.5% agarose gel electrophoresis. All PCR primer sequences are 
listed in Table S3. 
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Lentivirus Production, Titration and Transduction  
In order to increase the efficacy and maximize our results in cell lines we cloned selected gRNAs in the 
LentiCRISPRv2 vector (Addgene Plasmid #52961).35 
Research grade lentiviral vector production. Third-generation lentiviral vectors were produced by 
calcium phosphate transient transfection of 293T cells of the selected transfer vector, the packaging 
plasmid pKLg/p.RRE, pK.REV, the vesicular stomatitis virus glycoprotein G (VSV-G) envelope 
plasmid pK.G as previously described.49 
Lentiviral vector titration. Three hundred thousand (3 x 105) HCT116 cells were transduced with serial 
vector dilutions in the presence of polybrene (6 μg/ml). Genomic DNA (gDNA) was extracted 72 hours 
after transduction. gDNA is extracted by using MagNaPure 96 system (Roche Diagnostics, Promega) 
according to manufacturer’s instructions. Vector copies per diploid genome (vector copy number, 
VCN) were quantified by quantitative PCR (qPCR) starting from 100 ng of template gDNA using 
primers (HIV sense: 5’-TACTGACGCTCTCGCACC-3’; HIV antisense: 5’-
TCTCGACGCAGGACTCG-3’) and a probe FAM 5’- ATCTCTCTCCTTCTAGCCTC-3’) against the 
packaging signal region of LVs. Endogenous DNA amount was quantified by a primers/probe set 
against the human albumin gene (ALB sense: 5’ GCTGTCATCTCTTGTGGGCTGT-3’; ALB 
antisense: 5’-ACTCATGGGAGCTGCTGGTTC-3’; ALB probe: VIC 5’-
CCTGTCATGCCCACACAAATCTCTCC-3’). Copies per genome were calculated by the formula = 
[ng LV/ng endogenous DNA] x [n° of LV integrations in the standard curve]. The standard curve was 
generated by using a plasmid containing the appropriate sequences in cis from the vectors and ALB 
gene. Vector particles were measured by HIV-1 Gag p24 antigen immunocapture assay (Perkin Elmer) 
according to manufacturer’s instructions. Vector infectivity is calculated as the ratio between titer and 
particles.50 
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Titers obtained ranged from 5,8E8 TU/ml to 1.1E9 TU/ml. LV_int2.1, LV_int2.6 and LV_ex2.1 were 
used at MOI 20 together with 8ug/ml of polybrene in exon 2 duplicated myoblasts cell lines. 
 
Quantification of wild-type alleles created after removal of the exon 2 duplication by one gRNA 
Quantification of the efficacy of the gRNAs to remove the duplicated sequence at the DNA level was 
performed by Real-Time PCR using SsoFast EvaGreen Supermix (Bio-Rad) for 40 cycles and primers 
designed on the minimal common duplicated region (forward CCAAACCCATAGTCGTTCAAAT, 
reverse AGATGCTGCAAAGGAAGGAA) and on intron 67 of the DMD gene as control (forward 
GCATTTGGAAAGATTTGCTGA, reverse TGCTGGTGCAGACTTCTCTC). Real-Time PCR was 
performed in triplicate in 96-well plates using 50 ng genomic DNA from wildtype, untreated and 
lentiviral transduced cells. The calculation of the fold changes was based on the 2−ΔΔCT method 
(Applied Biosystems User Bulletin #2) and results were expressed in relation to the untreated cells set 
to 1. 
 
RNA analysis 
Total RNA was isolated from myotubes three days after differentiation using the RNeasy Kit (Qiagen) 
and reverse-transcribed by means of a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA), according to the manufacturer’s instructions. 
Before cDNA synthesis, RNA was treated with DNAse I (Roche, Branford, CT) and checked for 
residual DNA contamination by a 55-cycle PCR. 
RT-PCR of the exon 2 duplication was performed with Platinum Taq DNA Polymerase High Fidelity 
(Thermo Scientific) and oligos 21F and 448R (designed complementary to exon 1 and 4 of the DMD 
muscle isoform and taken from http://dmd.nl/) and resolved on 2% agarose gel. One microliter of the 
RT-PCR was loaded on High sensivity DNA chips (Agilent) for the quantification of the duplication 
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excision which was performed calculating the ratio of the area of the normal transcript and the sum of 
the area of normal and duplicated transcripts multiplied for 100 and normalized by setting to one the 
untreated (UT) samples. Experiments were performed in triplicate, mean results and standard 
deviations are shown. Significance was evaluated by Kluskall-Wallis test with post-hoc Mann-Whitney 
test for p-values less than 0.05 considered significant.   
 
Western Blot and Immunofluorescence analysis 
Immortalized myoblasts seeded in 30 cm Petri dishes and differentiated for ten days were washed with 
cold PBS and lysed in RIPA buffer in presence of Complete Mini protease inhibitor mixture (Roche) 
for 30 min on ice. Cell lysates were cleared and quantified.  
To check the expression of dystrophin, 30 μg of protein from myotubes were mixed with 4× NuPage 
LDS buffer (Invitrogen) supplemented with 50 mM DTT, heated for 2 min at 85 °C, loaded on Novex 
3–8 % Tris–Acetate Midi Gel (Invitrogen), and electrophoresed at 150 V with Tris–Acetate SDS 
running buffer (Invitrogen) for 70 min at RT. Proteins were then transferred at 45 V overnight at 4 °C 
onto PVDF membranes as described above using transfer buffer with no methanol. 
Membranes were blocked in TBS-T (20 mM Tris, 500 mM NaCl, pH = 7.5, 0.1 % Tween 20) 
supplemented with 3% (Dystrophin and Cas9) or 5% (alpha actinin) non-fat dry milk (Bio-Rad) for 1 
hour at room temperature (RT). 
Membranes were incubated for 1h at RT with rabbit polyclonal anti-Dystrophin (ab15266, Abcam), 
Anti-CRISPR-Cas9 (ab191468, Abcam) and mouse monoclonal α-actinin (Santa Cruz) antibodies, 
were washed three times for 10 min in TBS-T, incubated with immunopure goat anti-rabbit or rabbit 
anti-mouse IgGs (Dako) conjugated to horseradish peroxidase (HRP, 1:2000 in TBS-T 3 or 5% milk) 
for 1h at RT, and revealed with Pierce ECL Western Blotting Substrate (Pierce Biotechnology). 
Chemiluminescence was acquired by the ChemiDoc MP System (Bio-Rad) and quantified using 
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ImageJ 1.37v (NIH image). Immortalized control myoblasts differentiated into myotubes in vitro were 
used as positive control. 
In vitro differentiated immortalized wild type, #515 and #994 myoblasts were washed with PBS 
(Sigma-Aldrich), fixed with 4% paraformaldehyde (Sigma-Aldrich) at RT for 10 min and 
permeabilized with ethanol 75% (Sigma-Aldrich) at RT for 1 minute. As a blocking solution, 20% fetal 
bovine serum (Sigma-Aldrich) was used at RT for 30 minutes to reduce secondary antibody 
background signal. The cells were subsequently incubated overnight at 4°C with the anti-dystrophin 
(NCL-DYS2 Novocastra) primary antibody. After incubation, cells were washed with PBS and then 
incubated with the 594-fluorochrome conjugated secondary antibodies (Thermo Fisher) together with 
DAPI for nucleic acid staining (Ibidi) for 1 hour at RT in PBS containing 0.2% Triton X-100. After 
three successive washings with PBS, dishes were mounted using fluorescent mounting medium (Ibidi) 
and examined by fluorescence microscopy (DMI6000B, Leica). 
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FIGURE LEGENDS 
Figure 1 CGH profile of DMD exon 2 duplications and CRISPR design: (a) breakpoint analysis of 
DMD exon 2 duplications from different cohorts (Cochin, red; Bovolenta et al.27-28, purple, DelGaudio 
et al.29, green; White et al.30, turquoise) allowed us to identify the minimal common duplicated region 
(light blue shade); (b) Diagram representing the ~10kb of the minimal common duplicated region and 
the position and orientation of the gRNAs (orange) designed with ZiFiT website in respect to the exon 
2 of the DMD gene (green). The asterisks (*) indicate the mutation of the two patients tested in the 
present study.  
 
Figure 2: Detection of deletion and inversions after transfection of two gRNAs in myogenic cells. 
(a) Schematic representation of the 5.6 kb deletion created by transfecting the crDMDint2.1 and int2.6 
gRNAs in a control myogenic cell line. The primers used to amplify across the deletion breakpoint and 
the wild-type sequence are shown as coloured arrows: red, forward common primer; blue, wt specific 
reverse primer; green, deletion specific reverse primer. (b) PCR amplification and sequencing of the wt 
and deleted products. The PCR amplification revealed a product corresponding to the deleted sequence 
of about 1.1 kb only in treated cells (left panel, first lane) whereas the amplification of the wt sequence 
was obtained in both treated and untreated cells with a reduced amplification evident in treated cells. 
Sequence analysis of the deleted product showed the presence of two products with the only difference 
of a timine at the breakpoint causing a shifting starting from the shaded column (right panel).  
(c-d) Schemes representing the strategies used to amplify the deletions and inversions caused by two 
gRNAs. The same forward primer located upstream the first gRNA binding site (F1) was used in both 
approaches in combination with a reverse one downstream to the second gRNA binding site for 
deletions detection (c) and a second forward primer (F2) upstream the second gRNA binding site for 
inversions amplification (d). 
 27
(e) PCR products resulting from the amplification of the deletion breakpoints. The combination of the 
gRNAs used is reported above the image whereas the expected products size in base pairs is displayed 
below it. All the bands where excised and sequenced or directly sequenced (Fig. S2).  
(f) PCR products resulting from the amplification of the inversions breakpoints. The combination of the 
gRNAs used is reported above the image whereas the expected products size in base pairs is displayed 
below it. All the bands where excised and sequenced or directly sequenced (Supplementary Figure 2). 
A PCR product resulting from the nonspecific amplification was found in the second lane (i2.1/i2.3, 
upper band). An unexpected product was found in the fourth lane upon treatment with i2.1 and i2.6; 
sequencing reported the presence of a complex rearrangement and coexistence of an inversion and 
deletion between the two gRNAs (Fig. S2). 
T, treated; UT, untreated. 
    
Figure 3: DNA, RNA and protein expression analysis after infection with LentiCRISPRv2. (a) 
Histograms reporting the genomic analysis by real-time PCR of the duplicated sequence. Transduced 
cells present reduction of the duplication in respect to untreated cells (UT) set to 1. Wild-type cells 
were analysed as positive control. (b) RT-PCR was performed with primers designed on the exon 1 and 
4. One ul of the displayed PCR was loaded on a high sensitivity DNA chip and run on the Bioanalyser 
2100 (Agilent). Quantification of the peak obtained was performed calculating the ratio of the area of 
the normal transcript and the sum of the area of normal and duplicated transcript multiplied for 100 and 
normalized by setting the untreated (UT) as one. *p<0.05 (Kluskall-Wallis test with post-hoc Mann-
Whitney test from three independent experiments), ns: not significant. (c) Western blot from treated 
and untreated myotubes of patient 994 and 515, with antibodies against dystrophin, Cas9 and alpha 
actinin as loading normalizer. The amount of dystrophin was normalized to that of actinin by 
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densitometric analysis. WT, wild-type. (d) Immunocytochemistry of dystrophin (red) and nuclei (blue) 
in myotubes from patient 994. Scale bar = 1 μm. 
All error bars represent the standard deviation for three independent experiments. 
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TABLES 
Cells LV.CRISPR VCN (Total) VCN (LV.CRISPR)
515 - 3,4 - 
994 - 3,6 - 
515 LV_int2.1 4,1 0,7 
515 LV_int2.6 3,8 0,4 
515 LV_ex2.1 4,2 0,8 
994 LV_int2.1 6,6 3 
994 LV_int2.6 6,2 2,6 
994 LV_ex2.1 6,2 2,6 
 
Table 1: Vector Copy Number Analysis. LV, Lentivirus; VCN, Vector Copy Number. 
